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ABSTRACT
NFκB is implicated in breast cancer bone metastasis and skeletal remodelling. 
However, the role of IKKβ, a key component of the canonical NFκB pathway, in the 
regulation of breast cancer osteolytic metastasis has not been investigated. Here, 
we describe the cancer-specific contribution of IKKβ to bone metastasis, skeletal 
tumour growth and osteolysis associated with breast cancer. IKKβ is highly expressed 
in invasive breast tumours and its level of expression was higher in patients with 
bone metastasis. IKKβ overexpression in parental MDA-MD-231 breast cancer cells, 
promoted mammary tumour growth but failed to convey osteolytic potential to 
these cells in mice. In contrast, IKKβ overexpression in osteotropic sub-clones of 
MDA-MB-231 cells with differing osteolytic phenotypes increased incidence of bone 
metastasis, exacerbated osteolysis and enhanced skeletal tumour growth, whereas 
its knockdown was inhibitory. Functional and mechanistic studies revealed that 
IKKβ enhanced the ability of osteotropic MDA-MB-231 cells to migrate, increase 
osteoclastogenesis, and to inhibit osteoblast differentiation via a mechanism mediated, 
at least in part, by cytoplasmic sequestering of FoxO3a and VEGFA production. Thus, 
tumour-selective manipulation of IKKβ and its interaction with FoxO3a may represent 
a novel strategy to reduce the development of secondary breast cancer in the skeleton. 
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INTRODUCTION
Bone metastases and skeletal related events in 
patients with metastatic breast cancer are an important 
cause of morbidity, which place significant demands on 
health care resources [1, 2]. Clinical studies have shown 
that approximately 70% of breast cancer patients with 
advanced disease develop lytic bone lesions and suffer 
from skeletal-related events [1, 3, 4]. Breast cancer 
osteolytic metastasis develops and expands because 
of an interaction between tumour cells and local cells 
in the tumour microenvironment such as osteoclasts, 
osteoblasts and their precursors [1, 2]. Bone resorption by 
osteoclasts elicits the release of factors from osteoblasts 
                          Research Paper
Oncotarget16135www.oncotarget.com
and bone matrix that in turn stimulate tumour growth, 
exacerbate osteolysis and cause bone loss [1, 2]. Many 
tumour- and bone-derived factors have been implicated 
in the pathogenesis of bone metastases and osteolysis 
associated with breast cancer [4, 5]. However so far very 
few therapeutic targets have been identified. 
The nuclear factor-κB (NFκB) signaling pathway plays 
an important role in breast cancer progression, inflammation 
and bone cell activity [6]. The IκB kinase (IKK) complex, a 
key component of the canonical NFκB signalling pathway, 
is comprised of two closely related catalytic subunits, IKKα 
and IKKβ and a regulatory subunit IKKγ [6]. Ligand-
induced activation of IKK triggers the phosphorylation and 
recruitment of IKKα, IKKβ and IKKγ. Of the two catalytic 
subunits, IKKβ has emerged as the main regulator of 
osteoclast and osteoblast differentiation. Preclinical studies 
in mouse models of inflammation-induced bone loss and 
postmenopausal osteoporosis have shown that genetic 
inactivation or pharmacological inhibition of the IKKβ/NFκB 
signalling in bone cells inhibits osteoclastic bone resorption 
[7–10] and promotes bone formation [11, 12]. 
IKKβ is also implicated in breast cancer 
tumorigenesis and metastasis. High levels of expression 
and activity of IKKβ correlate with drug and radiotherapy 
resistance and poor clinical outcome in breast cancer 
patients [13–16]. A plethora of tumour-derived factors 
have been shown to regulate breast cancer tumorigenesis 
through activation of the IKKβ/NFκB signalling pathway 
[17–21]. Furthermore, accumulating recent evidence 
suggests that a host of oncogenic and cancer-driver 
pathways including c-Myc, Forkhead box O3A (FoxO3a) 
and PI3/Akt/mTOR regulate breast cancer cell metastatic 
behaviour through interaction with IKKβ [17–21]. 
There has been an increasing interest in the 
therapeutic targeting of the IKK/NFκB signalling pathway 
for the treatment of cancer associated bone disease. Both 
the canonical and non-canonical NFκB signalling pathways 
play a role in breast cancer bone metastasis [10], and we 
have previously reported that the small-molecule inhibitors 
of these pathways, Celastrol and Parthenolide, reduced the 
development of osteolysis in a rat model of breast cancer-
induced osteolysis [22]. However, the role of IKKβ, a key 
unit of the canonical NFκB signalling pathway, in the 
regulation of bone metastasis, skeletal tumour growth and 
osteolysis has not been investigated. Here, we report that 
IKKβ in sub-clones of the human MDA-MB-231 breast 
cancer cells with differing osteolytic phenotypes plays an 
essential role in bone metastasis, skeletal tumour burden 
and osteolysis associated with breast cancer.
RESULTS
IKKβ expression is enhanced in breast cancer 
bone metastasis
The canonical NFκB signaling pathway promotes 
breast cancer bone metastasis [10, 22]. Given that IKKβ 
is a key component of this pathway, we first assessed its 
expression in clinical datasets of human primary breast 
carcinoma and bone biopsies from breast cancer patients 
with known clinical outcome (Figure 1). A retrospective 
analysis of a cohort of patients with metastatic breast 
cancer [23] revealed that mRNA expression of IKKβ 
is elevated in primary breast carcinoma (Figure 1A, 
p = 0.00032, n = 185) and it is strongly associated 
with disease recurrence (Figure 1B, left panel, p = 
0.0001, n = 560) and bone metastasis relapse (Figure 
1B, right panel, p = 0.03, n = 560). To further evaluate 
the clinical importance and potential role of IKKβ in 
breast cancer bone metastasis, we performed detailed 
immunohistochemical assessment of IKKβ expression in 
breast tumours and lytic lesions in bone in biopsies from 
breast cancer patients who developed bone metastasis. As 
shown in Figure 1 (panels C–E), expression of IKKβ is 
clearly evident in breast carcinoma in situ (Figure 1C) and 
its level of expression were increased in invasive breast 
carcinomas (Figure 1C) and in lytic lesions (Figure 1C) 
when compared to breast carcinomas. Representative 
photomicrographs and Pie chart that show IKKβ 
expression in tumour biopsies and bone sections from 
breast cancer patient #3102/07 are shown in Figure 1, 
panels D and E, respectively. These results together 
indicate that cancer-specific expression of IKKβ is 
implicated in breast cancer bone metastasis. 
Cancer-specific IKKβ enhances mammary 
tumour growth
Metastatic breast cancer cells accumulate oncogenic 
alterations that affect their ability to metastasise to bone 
[24, 25]. With this in mind, we assessed the protein level 
of IKKβ in different clones of the triple-negative human 
MDA-MB-231 (MDA-231) and mouse 4T1 cells and their 
sub-clones with different propensity to metastasise to and 
colonize the skeleton. This experiment confirmed that 
IKKβ expression is significantly higher in the osteotropic 
human MDA-231-BT1 (moderate) and MDA-231-BT2 
(aggressive) (Supplementary Figure 1A), and mouse 4T1-
BT1 cells (aggressive) (Supplementary Figure 1B), when 
compared to their parental controls. In view of IKKβ 
being highly expressed in the osteotropic sub-clones of 
human MDA-231 breast cancer cells, we hypothesized 
that over-expression of IKKβ in parental MDA-231 cells 
conveys the capability to these cells to metastasise to bone 
from the mammary fat pads. Human MDA-231 breast 
cancer cells were chosen as a model of breast cancer bone 
metastasis in this study because the parental sub-clone of 
these cells has not previously been reported to metastasize 
to bone in mice after orthotopic injection in the mammary 
fat pad (unlike the 4T1 cells; Idris et al. unpublished data). 
Stable over-expression of IKKβ (Supplementary Figure 
1C) significantly enhanced tumour growth of parental 
MDA-231 cells after orthotopic injection (Figure 2A), 
as evidenced by increased tumour size (Figure 2B and 
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supplementary Figure 2A) and tumour weight (Figure 
2C–2D). Ki67 and CD31 staining of histological tissue 
sections revealed a greater number of proliferating cells 
(Figure 2E–2F) and CD31 positive vessels (Figure 2G–2H) 
in tumour biopsies from mice injected with MDA-231 
cells over-expressing IKKβ, indicative of enhanced 
tumour growth and angiogenesis, respectively. However, 
contrary to our hypothesis, IKKβ overexpression failed 
to convey metastatic capability to the parental MDA-231 
from the mammary fat pad to bone in the model described.
Figure 1: IKKβ expression is associated with high risk for bone metastasis. (A) Retrospective analysis of breast tissue samples 
showing increased expression of IKKβ in breast carcinoma when compared to normal breast tissue (n = 185: 143 normal and 42 invasive 
ductal carcinoma). (B) Increased expression of IKKβ is associated with breast cancer recurrence (left panel) and bone metastasis relapse 
(right panel) in patients (n = 560: 185, bone metastasis, 375, no bone relapse). Expression of IKKβ in the experiment described in panels 
A to B was determined by mRNA analysis. The most significant cut-point for high/low-IKKβ is shown (left panel). (C) IKKβ expression 
is increased in primary invasive carcinomas and bone metastatic lesions in a clinical dataset of matched primary tumour (n = 18) and 
bone biopsies (n = 5) from a breast cancer patient cohort. Expression of IKKβ in the experiment described in panel C was determined by 
Immunohistochemistry. Values are mean ± SD; **p < 0.01 and ***p < 0.001. (D–E) Representative photomicrographs (D) and Pie chart (E) 
show IKKβ expression in tumour biopsies and bone sections from patient #3102/07 from the breast cancer patient cohort described in C 
(right panel, black). the percentage of IKKβ positive cells that ranges from approximately 80% (bone metastasis) to 20% (normal tissue) 
of total tissue area. Values are mean ± SD.
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Cancer-specific IKKβ exacerbates osteotropic 
breast cancer cell metastasis to bone
Subsequently, we went to show that IKKβ 
overexpression enhanced the ability of two osteoporotic 
sub-clones of MDA-231 cells to cause bone metastasis 
in mice after intra-cardiac injection [26] (Figure 3A). 
Micro-computed tomography (MicroCT) and x-ray 
analysis revealed that all mice that received intra-
cardiac injection of the osteotropic MDA-231-BT1 
(moderately metastatic) and MDA-231-BT2 (highly 
metastatic) exhibited increased number of lytic lesions 
(MDA-231-BT1, 68% increase and MDA-231-BT2, 
90% increase, p < 0.05) (Figure 3B) compared to control 
mice. Furthermore, mice injected with the moderately 
metastatic sub-line MDA-231-BT1 overexpressing IKKβ 
experienced severe cachexia (Figure 3C, 40% increase 
after 55 days, p < 0.05) and became morbid and were 
sacrificed before 55 days compared to only 50% from 
the mock control group (p < 0.05) (Figure 3D). Of note, 
all mice injected with human breast cancer cells over-
expressing IKKβ exhibited evidence of metastases to 
the lungs when compared to mock control (data not 
shown). Detailed MicroCT of the tibial metaphysis of 
the sacrificed mice injected with human MDA-231-BT2 
(aggressive) cells overexpressing IKKβ at the end of 
the experiment showed a significant reduction in bone 
volume (Figure 3E, left and 3F), trabecular connectivity 
Figure 2: Cancer-specific IKKβ enhances primary tumour growth. (A) Graphic representation of orthotopic injection of 
parental human MDA-231 overexpressing IKKβ cells (IKKβOE) or their control (mockOE) into the mammary fat pads of adult mice. (B–C) 
Tumour size (cm3, B) and weight (gram, C) from the experiment described in panel A. (D) Representative photomicrographs of tumours 
from the experiment described. E) Percentage of Ki67 positive cells in tumour biopsies from the experiment described. (F) Representative 
photomicrographs of histological sections of tumours showing Ki67 from the experiment described. (G) Percentage of CD31 positive 
cells in tumour biopsies from the experiment described. (H) Representative photomicrographs of histological sections of tumour biopsies 
showing CD31 positive cells from the experiment described. Values are mean ± SD; *p < 0.05; **p < 0.01; ***p < 0.001.
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(decrease in connectivity density, Figure 3E, middle) and 
a more rod-like appearance of the trabeculae (increased 
structure model index, Figure 3E, right) compared to mock 
control. A detailed bone histomorphometric analysis of 
histological samples revealed that mice injected with the 
osteotropic MDA-231-BT1 cells overexpressing IKKβ 
exhibited dramatic increase in osteoclast number (Figure 
3G, left) and significant inhibition in osteoblast number 
(Figure 3G, right). Furthermore, IKKβ overexpression 
increased skeletal tumour growth when compared to the 
control group (Figure 3H). Collectively, these results 
demonstrate that cancer-specific IKKβ plays an essential 
role in the regulation of bone metastasis, skeletal tumour 
burden and osteolysis in the mouse model of human breast 
cancer described.
Cancer-specific IKKβ regulates breast cancer 
induced bone cell activity 
Next, we investigated the effects of manipulation 
of IKKβ on the interactions between osteotropic breast 
cancer cells, osteoblasts and osteoclasts in vivo, ex vivo 
and in vitro. All mice that received intra-tibial injection of 
human MDA-231-BT2 breast cancer cells suffered from 
osteolysis and bone damage as assessed by micro-CT 
analysis (Figure 4A–4C). In contrast, intra-tibial injection 
of MDA-231-BT2 deficient in IKKβ (Supplementary 
Figure 1E) caused less bone damage evident by increased 
bone volume, reduced trabecular separation and lytic 
area (Figure 4A–4C). Functional in vitro experiments in 
osteoblast and osteoclast cultures showed that exposure 
Figure 3: Cancer-specific IKKβ exacerbates bone metastasis and enhances skeletal tumour growth. (A) Graphic 
representation of intra-cardiac injection of the osteotropic MDA-231-BT1 (MDA-BT1, n = 16) and MDA-231-BT2 (MDA-BT2, n = 16) 
(55 days) overexpressing IKKβ (IKKβOE) or their control (mockOE) in adult BALB/c -nu/nu athymic mice. (B) Percentage of osteolytic 
metastasis incidence from two independent populations of osteotropic human MDA-231 breast cancer cell-lines (n = 16/group) from 
the experiment described in panel A as assessed by x-ray and microCT. (C–D) Percentage of cachexia (C) and survival (D) in mice after 
intra-cardiac injections of the osteotropic MDA-231-BT2 (n = 16) (55 days) overexpressing (IKKβOE) or their control (mockOE). (E) Bone 
volume (BV/TV, %, left) and trabecular connectivity (Conn.Dn., middle and SMI, right) after intra-cardiac injections of the MDA-231-BT2 
overexpressing (IKKβOE) or their control (mockOE) in adult BALB/c mice (n = 16) (up to 55 days). (F) Representative photomicrographs 
of microCT scan of tibial metaphysis of mice from the experiment described in panel E. Arrowheads denote osteolysis bone damage. (G) 
In vivo osteoclastogenesis (Oc.N, left panel) and number of osteoblasts (Ob.N, right panel) from tibial metaphysis of adult BALB/c mice 
from the experiment described in panel E (n = 16). H) Tumour area (% of tissue area) in tibial metaphysis of mice from the experiment 
described in panel C–G (n = 5, mockOE and n = 7, IKKβOE). Representative photomicrographs of tumour in tibial metaphysis of mice from 
the experiment described are shown in the left panel. Dotted line denotes tumour. Values are mean ± SD; **p < 0.01; ***p < 0.001. 
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to conditioned medium from osteotropic MDA-231-BT1 
cells overexpressing IKKβ increased osteoclast number 
(Figure 4D–4E) and inhibited osteoblast differentiation 
(Figure 4G), whereas these effects were revered in 
cultures treated with conditioned medium from IKKβ 
deficient cells. Further analysis of MDA-231-BT2 motility 
(Supplementary Figure 2B–2D) and growth (data not 
shown) confirmed that IKKβ overexpression and exposure 
with the osteolytic factor RANKL were both effective in 
significantly enhancing the migration of MDA-231-BT2 
cells, whereas knockdown and pharmacological inhibition 
of IKKβ activity in these cells were inhibitory. These 
results show that IKKβ plays an important role in the 
behaviour of osteotropic breast cancer cells in bone. 
Tumour-derived VEGF contributes to IKKβ-
driven osteolysis
To investigate the mechanisms by which cancer-
specific expression of IKKβ influence bone cell activity 
and osteolysis, we assessed conditioned medium 
induced osteolysis ex vivo and in immunocompetent 
adult mice (Figure 5A–5B). This experiment revealed 
that conditioned medium from MDA-231-BT1 cells 
overexpressing IKKβ caused more osteolytic bone 
damage in mouse calvarial bone in vivo (Figure 5A–
5B) and ex vivo (Figure 5C) when compared to control 
cells (p < 0.01). Conversely, calvarial bone exposed to 
conditioned medium from IKKβ deficient MDA-231-BT1 
Figure 4: Cancer-specific IKKβ enhances local osteolysis. (A) Graphic representation of intra-tibial injection of the osteotropic 
MDA-231-BT2 (MDA-BT2, n = 7 per group, 14 days) deficient in IKKβ (IKKβKD) or their control (mockKD) in adult BALB/c -nu/nu 
athymic mice. (B) Bone volume (BV/TV, %, left), trabecular separation (Tb.Sp., middle) and lytic area (% of tissue area, right) in tibial 
metaphysis of mice from the experiment described in A. (C) Representative photomicrographs of microCT scan of tibial metaphysis of 
mice from the experiment described in panels A–B. Arrowheads denote osteolysis bone damage. (D–F) In vitro osteoclast number (D), pre-
osteoclast proliferation (F) and osteoblast differentiation (G) after exposure to conditioned medium from control (mocksi), IKKβ deficient 
(IKKβsi) or over-expressing (IKKβOE) osteotropic human breast cancer cells. Representative photomicrographs of osteoclasts from the 
experiment described are shown in panel E. Values are mean ± SD; *p < 0.05; **p < 0.01; ***p < 0.001 from mock; +p < 0.01 from IKKβOE 
cultures.
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cells suffered less bone damage in vivo (Figure 5A–5B) 
and ex vivo (Figure 5C) (p < 0.01). Further detailed 
histological analysis of the calvarial bone from the ex 
vivo experiment described in Figure 5C showed that mice 
injected with conditioned medium from IKKβ deficient 
MDA-231-BT1 cells exhibited less osteoclasts (47%, 
p < 0.05, figure not shown) and higher bone volume 
(40%, p < 0.05, figure not shown) when compared to mice 
injected with conditioned medium from mock control 
cells. Representative photomicrographs of histological 
sections showing osteoclasts and osteolysis are shown in 
Figure 5, panels E and F, respectively. Similar effects were 
also obtained in ex vivo experiments using calvarial organ 
culture exposed to conditioned medium from osteotropic 
human MDA-231-BT1 cells (Figure 5C) and mouse 4T1 
breast cancer cells (data not shown). Encouraged by these 
findings, we employed an analytic approach that utilizes 
data from protein and gene expression arrays to attempt to 
identify the tumour-derived factor(s) responsible for the in 
vivo effects we observed. Analysis of the levels of human 
cytokines and chemokines in conditioned medium from 
mock and MDA-231-BT1 overexpressing IKKβ together 
with examination of the transcriptional responsiveness of 
these cells to changes in expression of IKKβ revealed that 
of all previously identified secreted bone metastasis factors 
[24, 25], only the expression of VEGF was significantly 
down regulated in response to IKKβ deficiency (p < 0.05, 
Figure 5G–5H). Analysis of a cohort of breast cancer 
patients with bone metastasis revealed that the expression 
of type A VEGF, but not B and C, is associated with 
disease occurrence (Supplementary Figure 3A). Moreover, 
VEGFA level was significantly elevated in conditioned 
medium from MDA-231-BT1 cells overexpressing IKKβ 
(Figure 5I) and mRNA expression was reduced in IKKβ 
deficient MDA-231-BT2 cells (Figure 5H). Consistent 
with this, the ability of MDA-231-BT1 overexpressing 
IKKβ cells to enhance RANKL-stimulated osteoclast 
formation was significantly reduced by antagonists of 
the VEGF receptor 1 and 2 when compared to mock 
control (Figure 5J), further confirming the involvement of 
VEGFA in IKKβ-driven osteotropic effects in the models 
described.
IKKβ engages FoxO3A in osteotropic breast 
cancer cells
During the course of this investigation, we observed 
that knockdown, overexpression and pharmacological 
inhibition of IKKβ in the osteotropic MDA-231-BT2 
had no significant effect on NFκB cytoplasmic retention 
and nuclear translocation (Figure 6A and 6B), despite 
significant changes of IKKβ kinase activity as measured 
by IκB phosphorylation (Supplementary Figure 1E) and 
degradation (Supplementary Figure 1F; knockdown - IκB 
phosphorylation - 78% reduction and IκB expression 
126% increase, p < 0.01). In contrast, both knockdown 
and pharmacological inhibition of IKKβ in these cells 
significantly reduced FoxO3a cytoplasmic sequestering 
and enhanced FoxO3a nuclear localisation, whereas 
IKKβ overexpression was inhibitory (20% increase in 
cytoplasmic retention, p < 0.01) (Figure 6C–6D). We 
also found that the expression of the pro-apoptotic protein 
FoxO3a is significantly reduced in patients with metastatic 
breast cancer (p = 0.0028, n = 185, Supplementary Figure 
3B). Functional studies in osteoclasts and MDA-231-BT1 
cell cultures demonstrated that knockdown of FoxO3a 
expression, but not p65NFκB, restored the ability of 
MDA-231-BT2 deficient in IKKβ to enhance osteoclast 
formation (Figure 6E). FoxO3a knockdown protected 
MDA-231-BT2 against the growth inhibition caused 
by IKKβ inhibition (Figure 6G). Together, these results 
implicate the IKKβ/FoxO3a axis in the regulation of 
osteotropic breast cancer cell behaviour (Figure 6H).
DISCUSSION 
The IKK/NFκB signalling pathway plays a 
role in the development of breast cancer [17, 21], and 
inflammation-induced bone loss [7–10, 22]. Previous 
studies implicated both canonical and non-canonical 
NFκB activation in the regulation of breast cancer bone 
metastasis [10], and previous work by our laboratories 
has found that pharmacological inhibition of these 
pathways reduces the progression of breast cancer 
osteolytic metastatic [22]. However, the role of IKKβ, 
a key component of the canonical NFκB pathway, in 
the regulation of breast cancer bone metastasis remains 
poorly understood. Here, we report that IKKβ expression 
in osteolytic lesions is higher than in primary tumours 
obtained from breast cancer patients, and we describe a 
previously unknown role of cancer-specific IKKβ in the 
regulation of bone metastasis, skeletal tumour burden, 
osteolysis and bone cell activity associated with breast 
cancer. Whilst overexpression of IKKβ in the parental 
MDA-231 human breast cancer cells have failed to convey 
bone metastatic potential to these cells, it significantly 
enhanced the osteolytic abilities of osteotropic human 
MDA-231 breast cancer cells in vitro, ex vivo and in vivo. 
Furthermore, IKKβ overexpression significantly enhanced 
skeletal tumour burden and increased the incidence 
of bone metastasis, exacerbated osteolysis, worsened 
cachexia and increased mortality in mice injected with 
two independent osteotropic sub-clones of MDA-231 cells 
with different metastatic abilities. Conversely, knockdown 
of IKKβ in the aggressive osteotropic sub-clone of MDA-
231 cells reduced their ability to cause osteolysis in both 
immuno-deficient and wild type mice. Although the effect 
of IKKβ knockdown/overexpression on breast cancer bone 
metastasis that we observed in this study were limited to 
the osteotropic MDA-231 breast cancer cells used, it is 
tempting to speculate that over-expressing IKKβ would 
likely have increased the ability of parental MDA-231 to 
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metastasise to bone after intra-cardiac injection in mice. 
When combined with previous studies on the role of IKKβ 
in primary breast tumour development [17, 21] and bone 
remodelling [8], the present findings suggest that IKKβ 
expression by both primary and osteotropic breast cancer 
cells plays an essential role in breast cancer. 
Breast cancer cells in the skeleton (osteotropic) 
acquire the capability to promote osteolysis by influencing 
the differentiation of osteoclasts and osteoblasts 
[4, 5, 27]. We, and others, have previously reported that 
pharmacological inhibition of NFκB activity reduced bone 
loss through inhibition of osteoclast bone resorption and 
Figure 5: IKKβ regulates osteotropic breast cancer cell behaviour by engaging VEGFA. (A) Total bone volume (BV/TV, %) 
in immunocompetent mice after supracalvarial injection of conditioned medium from control (mocksi/OE), IKKβ deficient (IKKβsi) or over-
expressing (IKKβOE) osteotropic human MDA-231-BT1 breast cancer cells (n = 7). Representative photomicrographs of microCT scans 
of calvarial bone of mice from the experiment described in panel B. (C) Ex vivo osteolysis (BV/TV, %) in mouse calvaria organ culture 
treated with conditioned medium (20% v/v) from control (mocksi/OE), IKKβ deficient (IKKβsi) or over-expressing (IKKβOE) osteotropic 
human MDA-231-BT1 breast cancer cells (n = 7). (D–F) Representative photomicrographs of microCT scan of calvarial bone (D) from 
the experiment described in panel C and histological sections showing TRAcP positive osteoclasts (E) and bone (F) from the experiment 
described in panel A–B. Arrowheads in panel E denote osteoclasts. (G) Heat map of VEGFA, B and C genes showing the differential 
mRNA expression between control (mocksi) or IKKβ deficient (IKKβsi) osteotropic human MDA-231-BT2 breast cancer cells. Green 
indicates repressed mRNA levels. (H) mRNA expression of VEGFA in control (mocksi) or IKKβ deficient (IKKβsi) osteotropic human 
MDA-231-BT2 breast cancer cells. (I) Protein level of tumour-derived VEGFA in conditioned medium from control (mockOE) or over-
expressing (IKKβOE) osteotropic human MDA-231-BT2 breast cancer cells measured by human VEGFA ELISA kit. (J) In vitro osteoclast 
formation in M-CSF and RANKL stimulated bone marrow treated with conditioned medium (20% v/v) from control (mockOE) or over-
expressing (IKKβOE) osteotropic human MDA-231-BT2 breast cancer cells in the presence and absence of the selective VEGFR 1 inhibitors 
VEGFinh1 (ZM306416, 1 μM) or VEGFinh2 (Ki8751, 1 μM). Dotted line denotes osteoclast number in vehicle treated mock control. Values 
are mean ± SD; *p < 0.05; **p < 0.01; ***p < 0.001; $p < 0.01 from vehicle treated mock (mockKD) control.
Oncotarget16142www.oncotarget.com
stimulation of osteoblast differentiation [7–9, 11, 12]. Our 
current data expand on these observations and demonstrate 
that selective inhibition of IKKβ in osteotropic breast 
cancer cells suppressed their ability to enhance osteoclast 
formation and to inhibit osteoblast differentiation. 
Mediators originating from skeletal tumours play a 
critical role in the regulation of the behaviour of breast 
cancer cells in bone [6, 28–30]. The NFκB signalling 
pathway is a well-established regulator of genes encoding 
various pro-inflammatory tumour-derived factors that 
are known to stimulate osteoclastogenesis, inhibit 
osteoblast differentiation, enhance angiogenesis and 
encourage tumour growth [17–21, 31]. Examination of 
the transcriptional responsiveness of osteotropic sub-
lines of the breast cancer cell line MDA-231 to IKKβ 
inhibition and overexpression revealed that VEGF was 
the only tumour-derived factor that was affected by 
manipulation of IKKβ expression in the osteotropic 
MDA-231 cells used. VEGFA is a potent stimulator of 
angiogenesis and is known to enhance the growth and 
motility of triple negative cells via NFκB activation 
[32, 33]. In the present study, we detected elevated level 
of VEGFA in conditioned medium from two clones 
of osteotropic MDA-231 cells overexpressing IKKβ 
consistent of the high rate of angiogenesis and tumour 
cell proliferation in tumours observed in vivo. VEGF 
is also known to enhance osteoclast formation [34, 35] 
and consistent with this we have found that blockage of 
VEGF receptor in pre-osteoclasts abolished the ability 
of human and mouse osteotropic breast cancer cells to 
enhance osteoclastogenesis and to migrate. We speculate 
that the likely mechanism for the osteoblast inhibition 
Figure 6: IKKβ engages FoxO3a in osteotropic breast cancer cells. (A) Differential expression of p65NFκB in cytoplasm (Cyt) 
and nuclear (Nuc) fraction obtained from control (mocksi/OE), IKKβ deficient (IKKβsi) or over-expressing (IKKβOE) osteotropic human 
MDA-231-BT2 breast cancer cells cultured in the presence and absence of the selective IKKβ inhibitors IKKβIII or IKKβV (10 μM). (B) 
Representative photomicrographs of the expression of p65NFκB, GAPDH and Lamin A/C from the experiment described in panel A. (C) 
Differential expression of FoxO3a in cytoplasm (Cyt) and nuclear (Nuc) fraction obtained from control (mocksi/OE), IKKβ deficient (IKKβsi) 
or over-expressing (IKKβOE) osteotropic human MDA-231-BT2 breast cancer cells cultured in the presence and absence of the selective 
IKKβ inhibitors IKKβIII or IKKβV (10 μM). (D) Representative photomicrographs of the expression of FoxO3a, GAPDH and Lamin A/C 
from the experiment described in panel C. (E) In vitro osteoclastogenesis of murine M-CSF and RANKL stimulated bone marrow after 
exposure to conditioned medium (10% v/v) from control (mocksi/OE), IKKβ deficient (IKKβsi), FoxO3a deficient (FoxO3asi), p65NFκB 
deficient (NFκBsi) osteotropic human MDA-231-BT2 breast cancer cells. (F) Representative images of TRAcP positive osteoclasts from 
the experiment described in panel E. (G) In vitro viability of control (mocksi/OE), IKKβ deficient (IKKβsi), FoxO3a deficient (FoxO3asi), 
p65NFκB deficient (NFκBsi) osteotropic human MDA-231-BT2 breast cancer cells. (H) Schematic model for the proposed mechanism of 
IKKβ regulation of FoxO3a and NFκB nuclear translocation in osteotropic breast cancer cells. Dotted red lines denote inhibition, green 
arrows denote activation and upward and downward black arrows denote increase and decrease, respectively. Values are mean ± SD; *p < 
0.05; ***p < 0.001; NS, non-significant.
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that was observed following exposure to conditioned 
medium from IKKβ overexpression cells is likely to 
be due to a relative increase in VEGFA production 
since VEGF is known to suppress the maturation and 
activity of cells of the osteoblastic lineage [35, 36]. In 
contrast, we found no evidence to suggest that IKKβ in 
human osteotropic breast cancer cells or in osteoblasts 
regulate the expression of Parathyroid hormone-related 
protein (PTHrP), tumour necrosis factor alpha (TNFα), 
transforming growth factor beta (TGFβ), and Interleukin 
6 (IL6) (data not shown), which all have been previously 
implicated in the regulation bone cell differentiation and 
activity [1, 2]. Notwithstanding this, we cannot exclude 
the indirect involvement of these essential mediators of 
osteolysis since VEGF and other tumour-derived factors 
are known to directly regulate their levels in osteoblast 
and osteoclasts [1, 2]. 
A major consequence of IKKβ activation is NFκB 
nuclear translocation and DNA binding [6, 37]. A 
surprising finding was that knockdown, overexpression 
and pharmacological inhibition of IKKβ failed to affect 
NFκB activation in the osteotropic MDA-231 breast 
cancer cells used. Our interpretation of these results is 
that tumour-derived factors in the conditioned medium 
– other than RANKL - activate NFκB via non-canonical 
and alternative pathways [6, 37–41]. During the course of 
this investigation, we became aware of studies that have 
reported that IKKβ binds, phosphorylates, and inhibits 
the pro-apoptotic transcription factor FoxO3a nuclear 
translocation [15, 21]. In agreement with the previously 
established role of FoxO3a in tumour growth [21, 42–46], 
osteoclast function and osteoblast differentiation [47], 
we have found that inhibition of IKKβ interaction 
with FoxO3a in osteotropic MDA-231 breast cancer 
cells overexpressing IKKβ inhibited their growth and 
diminished their ability to stimulate osteoclasts and to 
suppress osteoblast differentiation. In contrast, knockdown 
of p65NFκB in these cells had no effects. Whilst it is 
important to note that these findings do not exclude NFκB 
contribution to primary tumour growth, RANKL-induced 
osteoclast formation and osteoblast inhibition that have 
previously reported [48–51], our present data provide a 
plausible mechanism for the anti-migratory, anti-resorptive 
and osteoanabolic effects associated with IKKβ inhibition 
in the sub-clones of the osteotropic MDA-231 breast 
cancer cells used in this study.
Collectively, the results of the present study 
demonstrate that cancer-specific expression of IKKβ 
plays an essential role in the regulation of bone metastasis, 
skeletal tumour growth, osteolysis and enhanced bone cell 
activity associated with advanced breast cancer. These 
results offer new insight into the crosstalk between breast 
cancer cells and bone cells of the tumour microenvironment, 
and provide evidence to show that disruption of IKKβ and 
its interaction with FoxO3a may have potential therapeutic 
efficacy in all stages of breast cancer. 
MATERIALS AND METHODS
Reagents and cultures
The parental human breast carcinoma cell lines 
MDA-MB-231 (MDA-231) and 4T1 originated from 
the American Type Culture Collection and were in 
culture for < 6 months. The osteotropic sub-clones of 
the human MDA-231 (MDA-231-BT1 and MDA-231-
BT2) and mouse 4T1 (4T1-BT) cell-lines were generated 
by repeated passages in vivo [26]. The selective IKKβ 
inhibitors IKKβIII (401480) and IKKβV (401482) were 
purchased from CalBiochem (Dorset, UK); ZM306416 
(2499) or Ki8751 (2542) were purchased from Tocris 
Bioscience (Bristol, UK). All solvents and reagents were 
purchased from Sigma-Aldrich (Dorset, UK) unless 
otherwise stated. Tissue culture medium was obtained 
from Invitrogen (Paisley, UK). Human macrophage colony 
stimulating factor (M-CSF, 416-ML-050) was purchased 
from R&D Systems (Abingdon, UK). Receptor activator 
of NFκB ligand (RANKL) was a gift from Patrick Mollat 
(Galapagos, France). The targeting IKKβ and non-
targeting control siRNA were purchased from Thermo-
Dharmacon (CO, USA). The antibodies anti-IKKβ, IKKα, 
IKKγ, pIκB (ser32), IκB, FoxO3a, GAPDH and Lamin 
A/C were purchased from Cell Signalling Technology 
(Boston, MA, USA) and NFκBp65 was purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
Animal studies 
All procedures involving mice and their care 
were approved by and performed in compliance with 
the guidelines of Institutional Animal Care and Use 
Committee of University of Edinburgh (Scotland, UK) and 
University of L’Aquila (L’Aquila, Italy) and conducted 
in conformity with national and international laws and 
policies (UK Home Office regulations; Italian Legislative 
Decree 116/9 and, Gazzetta Ufficiale della Repubblica 
Italiana no. 40, February 18, 1992;). C57BL/6J and 
BALB/c nu/nu mice were obtained from Harlan (UK) and 
Charles River (Milan, Italy), respectively. 
Orthotopic injection of tumour cells
Four week‐old female BALB/c‐nu/nu athymic 
mice were anesthetized with intraperitoneal injections 
of pentobarbital (60 mg/kg). Cells (1 × 106 /50 μL PBS) 
were injected into the fat pad of the inguinal left breast 
(8 mice per group). Animals were daily monitored for 
cachexia (evaluated by body weight waste), behavior, and 
survival. The size of tumour was measured externally at 
least twice a week using a caliper and the formula of the 
volume of an ellipse [4/3 × π × (a × b × c)] was applied. 
Mice were euthanized by carbon dioxide inhalation after 
55 days from tumour‐cell injection. The primary tumours 
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and the lungs of the animals were dissected and processed 
as described in [26].
Intracardiac injection of tumour cells
Four week‐old female BALB/c‐nu/nu athymic 
mice were anesthetized and cancer cells (1 × 105 /100 μL 
PBS) were injected into the left ventricle (16 mice per 
group) [26]. The development of metastasis in bone was 
monitored by X-ray (36 KPV for 10 seconds, Faxitron 
model n.43855A; Faxitron X‐Ray Corp., Buffalo Grove, 
IL, USA) and in vivo micro‐computed tomography 
analysis (microCT; Skyscan 1172 scanner, Skyscan, 
Belgium) [26]. Radiographs were scanned using the Bio‐
Rad scanning densitometer (Hercules, CA, USA). Mice 
were euthanized and subjected to microCT analysis and to 
anatomical dissection for evaluation of bone and visceral 
metastases.
Intratibial injection of tumour cells
Seven four week‐old female BALB/c‐nu/nu athymic 
mice received intra-tibial injection cancer cells (5 × 
104 cells/ 20μL PBS) in the left leg [26]. Animals were 
euthanized 14 days (4T1) or 21 days (MDA-231) post 
injection and bones were analyzed by micro–computed 
tomography (MicroCT, Skyscan 1172 scanner). Skeletal 
tumor growth was measured on 2D microCT images using 
Image J (1.34s; NIH, Bethesda, MD, USA).
Supracalvarial injection of conditioned medium 
Three weeks-old wild type female C57BL/6J mice 
were injected over the calvarial bones with conditioned 
medium from cancer cells on 7 consecutive days. Mice 
were scarified 3 days after the last injection and bone 
density was assessed using microCT at a resolution of 
8 mm. No mice in this study exhibited any obvious 
physical signs of illness or inflammatory response.
Ex vivo experiments
Neonatal mouse calvarias were isolated from 7 day-
old mice, incubated in standard alpha-MEM for 24 hour 
and divided into equal halves along the median sagittal 
suture. Excised calvarial half was placed into culture on 
stainless steel rafts in 48-well plates in the presence and 
absence of cancer cells (1 × 104 cells/well). Tissue culture 
medium was changed every 48h hours and fresh control 
medium or medium containing test agents was added 
and the cultures were terminated after 7 days. For studies 
involving conditioned medium, conditioned medium form 
breast cancer cells (20% v/v) was prepared and added to 
the calvarial organ cultures. Calvarial bone density was 
assessed using microCT at a resolution of 5 mm.
Tumour histology, immunohistochemistry and 
histomorphometry
Orthotopic tumours were excised, fixed and 
embedded in paraffin. Sections were cut (5 μm) using 
a Reichert‐Jung 1150/Autocut microtome, incubated 
with antibodies and visualised using the Ultra‐Vision 
Detection System anti‐Polyvalent HRP/DAB kit according 
to the manufacturer’s instructions. Metastatic bones were 
embedded in methyl-methacrylate without decalcification. 
Von gieson-Von Kossa staining was performed to evaluate 
the tumour burden, Hematoxilin and Eosin staining 
for evaluating osteoclast parameters and toluidine blue 
staining for osteoblast. Histomorphometric measurements 
were carried out using an interactive image analysis 
system (IAS 2000, Delta Sistemi, Rome, Italy). 
Paraffin embedded material from human breast 
cancer and matched bone metastases were retrieved from 
the archive of Pathology Department of San Salvatore 
Hospital (L’Aquila, Italy). Histological sections were 
deparaffinized, incubated with 0.07 M citrate buffer (pH 6), 
15 min at 98° C, for antigen retrieval, treated with 3% 
H2O2 and incubated for 40 min at room temperature with 
the anti-IKKβ rabbit polyclonal antibody (Catalogue 
number: LS-B1362, LifeSpan BioSciences, Inc., Seattle, 
WA). The staining signals were revealed using the 
Dako LSAB+ System-HRP. Slides were counterstained 
with Mayer’s hematoxylin. Human placenta was used 
as positive control whereas negative controls were 
performed in parallel by omitting primary antibody for 
each case. IKKβ expression was evaluated in invasive 
primary carcinoma, in situ carcinoma (where present) and 
bone metastases and recorded as percentage of positively 
stained cells and staining intensity (%IKKβ, 0–40% is 
defined as week, 40–60 is defined as moderate and 60–
100% is defined as high). 
Small RNA interference
Cancer cells were transfected with siRNA (100 nM, 
Dharmafect 1 reagent, Dharmacon, CO, USA) according 
to the manufacturer’s instructions. Small interfering 
RNAs (siRNA; siGenome SMART pool) as a pool of 
four annealed double-stranded RNA oligonucleotides for 
IKKβ (M-003503-03) and their non-targeting control no. 
3 (D001201-03) (Dharmacon, CO, USA) were used. The 
efficiency of knockdown was determined by Western blot 
analysis. 
Generation of stable cell lines
To generate IKKβ expressing retroviruses 293T 
packaging cells (1 × 105 cell/cm2) were transfected with 
the 5 μg pMX retroviral vector (empty or containing 
IKKβ), 5 μg pCMV-Gag-pol vector, 5 μg pCMV-VSV-G 
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vector and 40 μl polyethylenimine. pLKO.1 puro lentiviral 
plasmid empty (TRC Lentiviral pLKO.1 Empty Vector 
Control RHS4080) or containing IKKβ-shRNA (TRC 
Lentiviral Human IKBKB shRNA RHS4533-EG3551 
glycerol set) were purchased from Thermo-Dharmacon 
(CO, USA). To generate IKKβ-shRNA expressing 
lentivirus 293T-packaging cells (1 × 105 cell/cm2) were 
transfected with the 5 μg pLKO.1 lentiviral vector (empty 
or containing IKKβ), 5 μg psPAX2 vector, 5 μg pCMV-
VSV-G vector and 40 μl polyethylenimine. Medium 
containing viral particles was collected, filtered applied 
immediately to MDA-231 cells, which had been plated 18 
hours before infection at a density of 1 × 104 cells/cm2. 
Polybrene (107689 Sigma-Aldrich Dorset, UK) was added 
to a final concentration of 5 mg/ml, and the retroviruses 
supernatants were incubated with the MDA-231 cells. 
Twenty-four hours after infections, cells were selected 
with 1mg/ml puromycin for 72 hours. 
Osteoblast cultures
Primary osteoblasts were isolated from the calvarial 
bones of 2-day-old mice by sequential collagenase 
digestion. For bone nodule assay, osteoblasts were 
seeded into 12-well plates (10 × 105 cells/well) for up 
to 21 days in αMEM supplemented with 10% FCS, 
penicillin and streptomycin, β-glycerol phosphate (10 
μM) and L-ascorbic acid (50 µg/ml). Osteoblast number, 
differentiation and bone nodule formation were determined 
by AlamarBlue assay, alkaline phosphatase (Alk Phos) 
assay and alizarin red (ALZ) staining, respectively. 
Activity of Alk Phos was assessed by a colorimetric assay, 
which measures the conversion of p-nitrophenyl phosphate 
to p-nitrophenyl in cell lysate and activity was normalized 
to cell number as determined by the AlamarBlue assay as 
previously described [52].
Osteoclast cultures
Osteoclast formation, survival and activity were 
studied using mouse RANKL and M-CSF generated mouse 
osteoclasts. Bone marrow (BM) cells were flushed from 
the long bones of 3–5 month old mice and were incubated 
for 48 hours in αMEM supplemented with mouse M-CSF 
(100 ng/ml). For osteoclast generation, M-CSF-generated 
bone marrow macrophages (osteoclast precursor cells) were 
cultured in αMEM supplemented with M-CSF (25 ng/ml) 
and RANKL (100 ng/ml). For studies involving conditioned 
medium, conditioned medium form cancer cultures was 
prepared in αMEM and added to osteoclast cultures (10% 
v/v). Osteoclasts were identified using TRAcP staining and 
manually counted on a Zeiss Axiovert light microscope.
Assessment of cell motility
The migration of cancer cells was assessed by 
wound healing assay [22]. Briefly, confluent cell layers 
were scored with a fine pipette tip and migration of cells 
was monitored using an Olympus ScanR time lapse 
microscope system. Percentage of wound closure were 
analysed using Tscratch analysis program. 
Western blotting
Cell monolayer was gently scraped in standard 
lysis buffer (0.1% (w/v) SDS, 0.5% (w/v) sodium 
deoxycholate, 1% Triton X-100, 1 μM EDTA, 2% (v/v) 
protease inhibitor cocktail, 10 mM of sodium fluoride 
and 2% (v/v) phosphatase inhibitor cocktail. For 
studies involving Cytoplasmic/Nuclear fractions, cell 
monolayer was scraped in Cytoplasmic lysis buffer (10 
mM Tris [pH 7.5], 0.05% NP-40, 3 mM MgCl2, 100 
mM NaCl, 1 mM EGTA) supplemented with protease 
and phosphatase inhibitor cocktail. Cell pellets were then 
re-suspended in complete RIPA lysis buffer and protein 
concentration was measured using BCA assay (Pierce, 
USA). Total protein (70 mg) was resolved by SDS-
PAGE on 12% polyacrylamide SDS gels, transferred onto 
PVDF membranes (BioRAD, UK) and immunoblotted 
with appropriate antibodies. The immuno-complexes 
were visualised by an enhanced chemiluminescence 
detection kit (Pierce, USA) using horseradish peroxidase-
conjugated secondary antibody (Jackson labs, UK), and 
then visualised using chemiluminescence (Amersham, 
UK) on a Syngene GeneGnome imaging system.
Measurement of levels of tumour-derived factors 
Levels of vascular endothelial growth factor 
(VEGF) in MDA-231 and 4T1 conditioned medium 
was determined by enzyme linked immunosorbent assay 
(ELISA) (R&D Systems, Abingdon, UK) and Proteome 
Profiler Human XL Cytokine Array Kit (ARY022, R&D 
Systems, Abingdon, UK), according to the manufacturer’s 
instructions.
Measurement of NFκB activity
Nuclear extracts from bone and cancer cells were 
prepared using a nuclear extract kit (Active Motif, 
Rixensart, Belgium) and DNA binding was measured 
using TRANSAM ELISA kit for p65 NFκB (Active Motif, 
Rixensart, Belgium), according to the manufacturer’s 
instructions.
RNA extraction and microarray 
Ribonucleic acid (RNA) was extracted using 
RNeasy Mini Kit with RNAse-free DNAse treatment 
(74014, Qiagen Crawley, United Kingdom), according 
the manufacturer’s instructions. 500 ng of total RNA 
from each sample was amplified and biotinylated using 
Illumina® TotalPrep RNA Amplification Kit (Ambion, 
AMIL1791), according the manufacturer’s instructions, 
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and then quantified using a Bioanalyser 2100. 750 ng of 
high-quality labeled cRNA per sample was hybridized 
to Illumina HumanHT-12v3 Expression Beadarrays in 
triplicate (Illumina, Cambridge, United Kingdom) using 
Whole-Genome Expression Direct Hybridisation kit 
(Illumina) and scanned with a 500GX (Illumina). The 
raw and normalized microarray data have been deposited 
in the Gene Expression Omnibus (GEO) database under 
accession number GSE71444. 
Analysis of clinical data
Retrospective analysis of IKKβ expression with 
respect to primary tumour growth and bone relapse was 
conducted using published cohorts of data. The MSK82, 
EMC192 and EMC286 datasets were directly integrated 
with batch-correction using ComBat. Exhaustive 
survival analysis was performed by considering all 
possible cut-points using the survivALL package. P 
values were derived from Wilcoxon test and were two-
tailed. Immunohistochemical analysis of IKKβ was also 
performed in cohort of 13 primary breast carcinomas and 
5 matched bone metastasis samples obtained from the 
Pathology Unit, San Salvatore hospital (L’Aquila, Italy), 
with informed consent from all subjects.
Statistical analysis
Results were reported as mean ± standard deviation 
(SD) as indicated in figure legends. A p-value value of 
0.05 or below was considered statistically significant. 
The half maximal inhibitory concentration (IC50) values 
were calculated using GraphPad Prism 4.0 for windows. 
Other comparisons were performed using unpaired two-
sided Student’s t test or analysis of variance (ANOVA) 
followed by Dunnet’s post test using SPSS for Windows 
version 11. Statistical analysis of the microarray data 
was performed using R and BioConductor packages. 
Quantile normalisation was performed using the lumi 
package. Comparisons between Kaplan-Meier curves were 
performed using the a log-rank (Mantel-Cox) test. Meta-
analysis was performed using Review Manager (RevMan), 
version 5.3 (Review Manager, 2014). 
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